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Introduction
Red blood cell (RBC) proportions of omega-3 and omega-6 fatty acids have well established relationships with a variety of disease phenotypes and risk factors, including total mortality [1] , acute coronary syndrome [2, 3] , serum lipid levels [4] , inflammatory markers [5] , cognitive function [6] and brain size [7, 8] among others. Variation in RBC omega-3 fatty acid levels (i.e.,
proportions, expressed as a percent of total fatty acids) have been shown to possess a strong heritable component [4, 9] , suggesting that not only dietary but also genetic factors likely play an important role in explaining differences between individuals [10, 11] .
Recently genome-wide association studies (GWAS) have sought to identify common single nucleotide polymorphisms (SNPs) with fatty acid levels. Initial investigations have focused on establishing potential relationships between plasma phospholipid fatty acid proportions and common SNP variations [12] [13] [14] [15] . However, mounting evidence suggests that this fatty acid pool may be more affected by recent fat consumption [16] , potentially obscuring the role of genetic variation in determining fatty acid composition [4, 17] .
Here we report a GWAS exploring relationships between the relative proportions of fourteen saturated, mono-and polyunsaturated RBC fatty acids with over 2.5 million common (minor allele frequency >1%) SNPs in the Framingham Heart Offspring Study.
Materials and Methods

Sample
Our analysis focused on the Framingham Heart Study (FHS) Offspring sample, a population based longitudinal study of families living in Framingham, Massachusetts. Detailed descriptions of the sample are available [4, [18] [19] [20] . The final sample for this study consisted of 2633 individuals for whom both fatty acid and genotype data were available. The 2633 is a subset of 2899 Offspring subjects attending Examination 8 (2005 Examination 8 ( -2008 ; those excluded due to missing genotype data had similar demographic and fatty acid profiles as those included in the study (data not shown). Written informed consent was provided by all participants, and the Institutional Review Board at the Boston University Medical Center approved the study protocol.
Fatty acid measurements
The fatty acid composition of RBC samples were analyzed by gas chromatography equipped with a SP 2560 capillary column after direct transesterification for 10 minutes in boron trifluoride/ methanol and hexane at 100 C as previously described. [4] . This technique generates fatty acids primarily from RBC glycerophospholipids. All fatty acids with at least 0.5% abundance were included for analysis (except trans oleic acid): arachidonic acid (AA), dihomogamma-linoleneic acid (DGLA), docosahexaenoic acid (DHA), docosapentaenoic acid-n3 (DPAn3), docosapentaenoic acid-n6 (DPA-n6), docosatetraenoic acid (DTA), eicosapentaenoic acid (EPA), linoleic acid (LA), oleic acid (OA), palmitic acid (PA), and stearic acid (SA). Three fatty acids below the 0.5% abundance level were also included: Palmitoleic acid (POA), because it is a marker of de novo lipogenesis [21] ; gamma-linolenic acid (GLA), because it is the initial product of LA metabolism via delta-6 desaturase [22] ; and alpha-linolenic acid (ALA), because as a dietary essential fatty acid like LA, its levels should be under less metabolic control than fatty acids that are the products of metabolism. Means and SDs of all 14 FAs are provided in Supplemental Table 1 .
Genotype data
This analysis is based on approximately 2.5 million autosomal CEU (Centre d'Etude du Polymorphisme Humain collection from Utah; Northern and Western European ancestry)
HapMap SNPs which were measured directly (approximately 550,000) or imputed (approximately 2 million) as previously reported [18] . Briefly, direct genotypes were obtained using the Affymetrix 500K and MIPS 50K chips, and were analyzed at the Affymetrix Core Laboratory. SNPs with missing data rates more than 3%, Hardy Weinberg Equilibrium p-values less than 1x10 -6 , more than 100 Mendelian errors or low minor allele frequency (less than 1%)
were eliminated from consideration. Measured SNPs, along with HapMap (release 22, build 36, CEU reference panel) [23] was used to impute the remaining 2 million SNPs using MaCH [24] .
Quality control procedures were similar for both imputed and directly measured SNPs, with the addition of standard imputation quality metrics for imputed SNPs (see [18] for details).
Statistical analysis
For each of the 14 fatty acids considered here, a linear mixed model was fit for each of the 2.5 million SNPs which passed the initial quality control criteria. Each regression model predicted log 10 -transformed fatty acid level by SNP genotype (number of minor alleles), adjusting for age, sex and a random covariance component summarizing the family-structure present in the Framingham data set (i.e. matrix of kinship coefficients). We reported partial 2 r values in the text, which were percent change in the log of the relative fatty acid proportion explained by one additional minor allele (i.e. additive genetic model). Linear mixed effects models using the kinship matrix were run using R (lmekin function) for all analyses [25] . SNPs were considered genome-wide significant if their p-value was less than 1x10 -8 . For each fatty acid, the distribution of p-values was evaluated using a Q-Q plot, and the genomic control lambda value (Ȝ GC ) was 
Results
The clinical characteristics for the FHS Offspring participants and their fatty acid levels have been previously reported [4] ; briefly they had a mean (SD) age of 66 (9) years, 54% were female, 9% smoked, and nearly half were treated for hypertension (49%) and high cholesterol (43%). They also had the following comorbidities: diabetes (14%), coronary heart disease (11%), and congestive heart failure (3%).
In all, 470 linear mixed models of SNP-fatty acid combinations reached a genome-wide significant p-value of less than 1x10 -8 (Supplemental Table 2 ). Since some SNPs were related to multiple fatty acids, there were a total of 191 different (i.e., uniquely associated) SNPs reaching genome-wide significance for at least one fatty acid (see Supplemental Table 3 ). In general, when multiple fatty acids were associated with the same SNP, the fatty acids were correlated (details not shown), in part because they are often in the same metabolic pathway. Table 1 provides an overview of the five associated regions, summarizing location information, the number of significantly associated SNPs, references to prior literature about the functionality of the region and a listing of the associated fatty acids.
Chromosome 1
The single significant SNP in chromosome 1 (rs3811444) is located in TRIM58 (tripartite motif containing 58), a gene located in 1q44 from base pair (bp) 248,020,501 to 248,043,440. SNP rs3811444 is a C (common allele) to T (rarer allele) polymorphism, with T alleles associated with lower levels of OA (partial 2 r =1.6%).
Chromosome 3
Three SNPs in and nearby to the PCOLCE2 (alt: PCPE2; procollagen C-endopeptidase enhancer 2) gene were significantly associated with AA levels (rs2248811, rs6778966, rs2581624) with pvalues ranging from 8x10 -9 to 1. Figure 1 depicts the regional association of AA on chromosome 3 near PCOLCE2, showing that three significant SNPs are highly correlated. Table 2 shows that rs2581624 explained 1.6% of the change in AA.
Chromosome 6
Thirteen SNPs within a 46kb region of chromosome 6 were significantly related to DPA-n3 levels. This region contains two genes: SYCP2L (synaptonemal complex protein 2-like) and ELOVL2 (ELOVL fatty acid elongase 2), which are located from 10,887,064 to 10,974,542 and 10,980,992 to 11,044,624, respectively. Seven of the significant SNPs were contained within SYCP2L, five within ELOVL2 and one in the intergenic space between the two genes. All significantly associated SNPs in this region had similar explanatory power (partial 2 r values between 1.2 and 1.3%). Figure 2 illustrates that the genome-wide significant SNPs in the ELOVL2-SYCP2L region are in linkage disequilibrium.
Chromosome 11
The majority of 141 associated SNPs on chromosome 11 were contained within a 488kb region of chromosome 11. This region contains nine distinct genes, with many of the genes (FADS2, FADS1, FEN1, C11ORF9 and C11ORF10) showing associations with approximately half of the fatty acids in our analysis. The remaining genes (BEST1, RAB3IL1, FADS3 and DAGLA) show associations with between one and three fatty acids (see Table 2 for details). Full results are provided in Supplemental Table 3 which provides p-values, minor allele frequencies and effect size estimates for the SNPs in the region. We briefly describe three distinct subregions.
Our analysis identifies twenty-nine significant SNPs in the region in and upstream of DAGLA (Diacylglycerol lipase, alpha; bp 61,119,554 to 61,273,052), showing associations with DGLA levels for all SNPs, plus with AA for two of the twenty-nine SNPs. Associations with DGLA levels were generally negative, though some SNPs showed positive association (partial 2 r between 1.7 and 3.4%; see Supplemental Table 3 for details).
The FADS genes (FADS1; FADS2; FADS3; fatty acid desaturase), along with nearby ORFs (C11ORF9, FEN1 and C11ORF10) contain or are nearby to 86 significant SNPs, with most SNPs associated with multiple FA, and widely varied direction and magnitude of effect (see Supplemental Table 3 for details). Figure 3 shows the high correlation between associated SNPs throughout the FADS region. Table 2 shows that SNPs in this region accounted for as much as 42% of the variability in DGLA levels.
Remaining SNPs near or contained in RAB3IL1 (RAB3A interacting protein; 13 SNPs) and within or downstream of BEST 1 (Bestrophin 1) were mainly positively associated with DGLA levels, with a handful of SNPs also related AA and LA levels (see Supplemental Table 3 for details).
Chromosome 12
All 33 significant SNPs on chromosome 12 are within a single 112 kb region which contains multiple genes (PTPN6, PHB2, MBOAT5 (alt. LPCAT3) and C1S). These SNPs all show association with OA and LA. Rare alleles were generally associated with lower OA levels and higher LA levels, corresponding to the negative association between these two fatty acids in the sample. Figure 4 illustrates the regional association for OA, showing strong correlation between the genotypes of significant SNPs in this region (a similar effect is observed for significant LA SNPs in this region). SNPs in this region accounted for as much as 4-8% of variation in LA and OA levels (see Table 2 ). Table 3 illustrates the overall variation explained (model 2 r ) for each of the eight fatty acids with at least one genome-wide significant SNP. In particular, a separate model predicting the log-transformed fatty acid relative proportion for each of the eight fatty acids was predicted by age and sex, and then all significant SNPs for the fatty acid were added to the model. In cases where SNPs showed strong association with each other (Pearson correlation between genotypes greater than 0.7), only one individual SNP from that group was added to the model. The model predicting DGLA had the largest overall variability explained (53.5%), and only 0.1% of this estimate was associated with age and sex. Models predicting AA, LA and OA explained 13.7%, 10.5% and 8.3% of the variation in the relative proportions of these fatty acids, respectively, with all three models showing large improvements over models containing only age and sex (13.6%, 8.9% and 7.8% improvement, respectively). Models for ALA and DTA explained similar amounts of overall variation (8.9% and 9.9%), but were driven largely by age and sex and not SNP genotypic variation (1% and 1.6% improvement with SNP genotypes). Finally, models for GLA and DPA-n3 explained less variation overall (6.1% and 6.4%), with approximately twothirds of the variation explained by age and sex (1.5% and 2.6% improvement with SNP genotypes).
Multivariable models
Discussion and Conclusions
This report presents the results of the largest genome-wide association study of RBC fatty acid composition to date. In our exploration of potential associations between 14 fatty acids and 2.5 million SNPs, we identified five distinct regions yielding associations reaching genome-wide significance. Of these, two of the regions replicated prior results from genome-wide association studies GWAS of serum fatty acid levels (Chromosome 6 (ELOVL2); Chromosome 11 (FADS genes)), two were novel (Chromosome 3 (PCOLCE2) and Chromosome 12 (LPCAT3)) and one identified a SNP on Chromosome 1 (TRIM58) with prior evidence of association to platelet and RBC counts. We briefly discuss each of these distinct regions in light of their known biology and prior GWAS evidence.
TRIM58
TRIM58 contains only a single significant SNP-fatty acid association. However, this SNP was recently identified as significantly related to platelet [27] and RBC counts [28] in European populations. The TRIM58 gene has also been associated with mean corpuscular volume in a Japanese sample [29] . Despite prior association evidence with related phenotypes, its function has no clear relationship with fatty acid metabolism. In addition, previous studies with fish oils have not shown effects on platelet counts [30] (except with supraphysiological intakes [31] ), but do affect platelet function [e.g., aggregation [32, 33] , thrombin generation [34] , activation].
PCOLCE2
To date fatty acid GWAS have not uncovered associations with SNPs in PCOLCE2. PCOLCE2 encodes the protein PCPE2 [35] which regulates apoA-I maturation [36] , modulating apoA-I levels [37] . ApoA-I is the major structural component of high density lipoproteins (HDL). While its role in reverse cholesterol transport is well known, HDL also transports a large portion of plasma phospholipids, of which arachidonic acid (AA) is a major component. This provides a plausible biological mechanism whereby SNPs could impart less effective maturation of apoA-I, which could result in lower plasma HDL levels. Since HDL particles transport about 40% of the plasma phospholipids, and since RBC membrane phospholipids exchange with lipoprotein phospholipids (which carry AA), it is conceivable that SNPs in PCOLCE2 could impact RBC membrane AA composition [38] . HDL levels themselves are strongly and repeatedly related to cardiovascular disease outcomes [39, 40] and this observation could reveal underlying mechanisms, though recent evidence suggests all genetically-determined differences in HDL levels are not consistently associated with differences in cardiovascular disease risk and, further, that using HDL cholesterol as a target for therapy (i.e., intervening to raise low levels) is ineffective at reducing risk for cardiovascular disease risk [41] .
ELOVL2
Previous studies have identified SNPs in both ELOVL2 and the nearby gene SYCP2L as being significantly related to fatty acid proportions in plasma phospholipids. In particular, Lemaitre et al. [12] identified 2 SNPs in SYCP2L (rs6918936 with EPA levels and rs4713103 with DPA and DHA levels). Both SNPs were identified as significant in our analysis, though only showing significant association with DPA; DHA only attained sub-threshold significance (both with p=2x10 -6 ), and EPA even less (p>0.001) (details not shown). Additional SNPs within ELOVL2
have also been associated with plasma phospholipid fatty acid patterns, metabolite levels and other metabolic traits [12, 13, 42, 43] . Many of these SNPs are replicated in our analysis (details not shown).
ELOVL2 on chromosome 5 encodes a long chain fatty acid elongase. The elongase is one of seven ELOVL-family proteins that act primarily on polyunsaturated fatty acids [44] and ELOVL2
is critical in the elongation of DPA n-3 to DHA [45] (see also Supplemental Figure 2 ). The strong direct associations between DPA n-3 levels and SNPs in this gene provide further evidence of this relationship. In the transformation of DPA-n3 to DHA, elongation to tetracosapentaenoic acid (TPA; more commonly 24:5n3) by ELOVL2 is a key step, and SNPs contributing to reduced efficiency in this process would be expected to produce more DPAn3, less TPA, and less DHA as the end product. On the other hand, a functional mutation in ELOVL2
could also slow the synthesis of DPA n-3 from EPA. Although it is difficult to predict how these two counterbalancing processes might affect DPA n-3 membrane content, our finding of a direct relation between DPA n-3 and SNPs in ELOVL2 suggest, as have Gregory et al. [45] , that conversion to TPA may be the more rate-limiting step. We did not measure TPA, but it is worth noting that while DHA did not achieve our threshold of significance, it was negatively associated with the presence of many SNPs (1x10 -5 <p<5x10 -7 ; details not shown). This evidence combined with evidence from previous GWAS studies suggests that genetic variability may influence the levels of long-chain polyunsaturated omega-3 fatty acids.
FADS
Our analysis identified many strong association signals on chromosome 11, all in or near the FADS gene region which is well-documented to be associated with fatty acid proportions [12, 13] . The FADS genes (FADS1, FADS2 and FADS3) are fatty acid desaturase genes. The proteins encoded by these genes are key enzymes involved in the the desaturation of n-3 and n-6 polyunsaturated fatty acids as follows: FADS1 desaturates at the delta-5 position [e.g., the conversion of DGLA (20:3n6) to AA (20:4n6)] and FADS2 desaturates at the delta-6 position [e.g., the conversion of LA (18:2n6) to GLA (18:3n6)] [22, 46] . FADS3 has non-specific, or currently ill-defined desaturation activity (see also Supplemental Figure 2 ). Recent work has identified two major haplotypes spanning FADS1 and FADS2. Our analyses support the presence of these haplotypes in this sample, as well as the finding that the more common haplotype is associated with increased efficiency of long-chain fatty acid synthesis [47] .
Furthermore, these genes have been shown to be associated with a number of phenotypes in SNP association studies, including certain plasma fatty acids [48, 49] , plasma lipoproteins [48, 50] , and response to lipid therapy [51] as well as DNA methylation levels [52] .
A nearby gene in which SNP associations were found (DAGLA) encodes diacylglycerol lipases alpha. Two of the SNPs (rs1692120 (upstream) and rs198426 (within DAGLA)) found to be significantly associated in our analysis have been shown in prior research to have significant associations with DPA and ALA [12] . The lipase is a key enzyme in endocannabinoid synthesis pathways [53] and has been previously identified as associated with plasma phospholipid n-3 fatty acids in the CHARGE consortium [12] . Endocannabinoids modify risk-related patterns including having an effect on eating behavior. An association of diacylglycerol lipase SNPs with the RBC membrane fatty acid composition is not necessarily intuitive, nor is it immediately apparent why association are with increasing DGLA levels. It is also not apparent that the association is because of endogenous RBC-DAGLA activity [54] or is a secondary consequence of its activity in other tissues.
LPCAT3 (alt. MBOAT5)
Little to no evidence exists in the GWAS literature connecting this region of chromosome 12
with fatty acid and other phenotypes. LPCAT3 encodes lysophosphatidylcholine acyltransferase 3, yielding a protein which mediates the transfer of fatty acids between glycerol-lipids. LPCAT3
favors the transfer of saturated, as opposed to unsaturated, fatty acids [55] . While other LPAT genes have been identified in GWAS studies on lipid endpoints or, shown to be associated with cardiovascular risk [48, 56] , LPCAT3 is a novel observation with SNPs explaining a modest amount of variation in LA and OA. The sn2 position of phospholipids primarily carries polyunsaturated fatty acids, and limitation of LPCAT3 activity increases the abundance of polyunsaturated fatty acids, such as linoleic acid, over monounsaturated fatty acids such as oleic acid as observed here. Given the general interest in altering the relative abundances of these two fatty acid classes this association could provide valuable insight to underlying biology.
The only published reports correlating RBC fatty acid composition to endpoints in the Framingham Offspring Cohort focused on the long-chain omega-3 fatty acids EPA and DHA or trans fatty acids [4, 7] . It is important to note that none of the SNP -fatty acid relations observed in this current analysis found significant associations for any of these fatty acids. This is perhaps because RBC levels of these fatty acids are more strongly determined by variations in dietary intake than are any other fatty acids [57, 58] . However, other explanations are also possible (see following paragraph for some details). We previously reported that "heritability" explained much of the variability in RBC EPA+DHA (the Omega-3 Index) in this cohort [4] . When estimates of EPA+DHA intake (from food and supplements) were added to the model, the proportion of variability assigned to heritability diminished from 50% to 32%, suggesting that commonalities in eating patterns among families accounted for a large portion of heritability. In the present analysis, dietary fatty acid intake was not taken into account (since fatty acid intake data were not available for 1/4 of the cohort), and thus our ability to detect genetic influences was likely diminished due to unaccounted effects of diet on RBC fatty acid patterns. Other efforts have suggested 40-70% of variation in fatty acids is accounted for by genetic variation [9] . However, multiple types of genetic information from very large cohorts may be needed to reveal genetic vs. non-genetic influences in phenotypes [59] .
Limitations
While this analysis has yielded a mix of biologically plausible novel genetic loci, as well as replicating prior genome-wide associations, there are a few limitations worth noting. The first was the lack of dietary data (especially relevant for EPA and DHA) described above, with the related issue that proportions of multiple RBC fatty acids can be highly inter-correlated [4] .
Further work is necessary to develop fatty acid-specific models that leverage dietary covariates, that explicitly model the complex correlation structure between fatty acids, and that consider ratios of fatty acids as opposed to single fatty acids. Second, our analysis only considers common variants. Exome sequencing of the Framingham Offspring cohort is ongoing, and future analyses should consider the potential role of rare genetic variation in explaining fatty acid levels. Third, the family structure of the Framingham data meant that the effective sample size for our analysis was lower than the actual sample size of 2,633, limiting power to identify associated SNPs.
Fourth, as is the case with any genome-wide association study, use of conservative significance levels, as we have done here, provides protection against false positives, but can lead to reduced ability (low power) to identify additional phenotype-genotype associations. Alternative methods (e.g., candidate gene/pathway analyses that build more biologically-informed statistical models), combining this sample with others, or gathering additional larger samples will be needed to further characterize potential gene-fatty acid relationships. These further analyses should also consider the potential role that rare (MAF<1%) genetic variation may play in fatty acid metabolism. Finally, replication of the novel loci identified in this paper should be sought after in independent samples, along with consideration of impact of causal loci on gene expression and associations with DNA methylation.
Conclusions
In seeking SNP relations for fourteen red blood fatty acid levels, we identified three novel loci, and replicated two others. Further work is needed to fine map the new regions of genetic interest (PCOLCE2, LPCAT3 and TRIM58) in independent samples, and analyze data using more biologically-informed models to potentially establish causal relationships between genetic variation and fatty acid metabolism.
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